Neuroendocrine Tumors Clinical Trial
Official title:
Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors
Background:
- Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The
only treatment for NETs is surgery, but most are found when they are too advanced for
surgery. Researchers are looking for the best way to find NETs earlier, so that surgery can
be successful. They want to test if the study drug can be used along with imaging devices to
detect NETs.
Objectives:
- To see how well a new experimental imaging agent, 68Gallium-DOTATATE, detects unknown
primary and metastatic NETs in the gastrointestinal system and pancreas.
Eligibility:
- Adults over 10 years old with a suspected NET or family history of NET.
Design:
- Participants will be screened with a medical history and physical exam, and have a blood
test.
- Participants will undergo three scans. For all of these, a substance is injected into
their body, they lie on a table, and a machine takes images.
- A standard computed tomography (CT) scan of the chest, abdomen, and pelvis.
- An octreotide scintigraphy Single photon emission computed tomography (SPECT)/CT.
- A 68Gallium-DOTATATE positron emission tomography (PET)/CT. The study drug is injected
into a vein, usually in the arm. Low-dose X-rays go through the body. For about 40
minutes a large, donut-shaped device takes images of the body. The entire session takes
90 to 120 minutes.
- Researchers will compare images from the three scans.
- Participants will have 1 follow-up visit each year for 5 years. At this visit, they will
have a medical exam, blood taken, and a CT scan.
Background:
- Neuroendocrine tumors (NETs) are rare malignancies occurring in the gastrointestinal
tract, islets of the pancreas, lung, adrenal medulla and thyroid C-cells.
- Their incidence has increased over the last decade, with an incidence of 6 per 100,000
persons a year and they represent 0.46% of all malignancies.
- Most NETs are sporadic, but they can be part of familial cancer syndromes such as
multiple endocrine neoplasia type 1 (MEN1), MEN2, and neurofibromatosis type 1 (NF1) or
Von Hippel-Lindau (VHL) syndrome.
- Surgical resection remains the only curative treatment option for patients with NETs but
80% of patients are diagnosed with advanced (metastatic, locally inoperable, or
recurrent) disease.
- The main prognostic factor in patients with NET is the extent of disease.
- The best imaging technique for detecting unknown primary and metastatic NETs has yet to
be determined.
- NET cells express somatostatin receptors that can be targeted with radiolabeled
68Gallium-DOTATATE (Octreotate) for imaging purposes.
- The primary goal of this protocol is to determine the accuracy of a new somatostatin
receptor targeted imaging technique, using 68Gallium-DOTATATE PET/CT to detect unknown
primary and metastatic NETs.
Objectives:
-To determine the accuracy of 68Gallium-DOTATATE PET/CT scans in detecting unknown primary
and metastatic gastrointestinal and pancreatic neuroendocrine tumors.
Eligibility:
- Patients with:
- suspicion of NET on axial imaging (CT/magnetic resonance imaging
(MRI)/fluorodeoxyglucose-positron emission tomography (FDG PET) and/or
- biochemical evidence of NET (serum/urinary) based on elevated levels of
chromogranin A, pancreatic polypeptide, neuron-specific enolase, vasoactive
intestinal polypeptide, serotonin (urinary 5-HIAA), gastrin, somatostatin,
catecholamines, metanephrines, calcitonin, fasting insulin, C-peptide (proinsulin),
glucagon and/or
- familial predisposition to NET in patients with multiple endocrine neoplasia type 1
(MEN1) and VHL.
- Age greater than or equal to 18 years of age.
- Patients must be willing to return to National Institutes of Health (NIH) for follow-up.
Design:
- Prospective study.
- A 68Ga-DOTATATE PET/CT scan will be done in patients with suspicious lesions, unknown
primary tumor or metastatic gastrointestinal or pancreatic neuroendocrine disease found
on anatomic imaging (CT/MRI) or in patients having biochemically active disease.
- Both functional and non-functional solid tumors will be included in this study.
Furthermore, asymptomatic and symptomatic, sporadic and familial cases of NETs (such as
Von Hippel-Lindau (VHL), MEN1) will be included.
- Demographic, clinical and pathologic data will be collected from the medical record and
patient interview for each patient. Data will be stored in a computerized database.
- After their initial on-study evaluation, patients will be staged according to findings
on imaging studies with respect to primary tumor site, size and metastases. Surgical
resection of NET and/or medical managements will be recommended based on standard
practice guidelines. In patients who undergo surgical treatment, the samples will be
immediately stored until molecular analysis.
- Follow up will be done yearly for a total duration of 5 years. This includes a yearly
imaging study and a biochemical and clinical evaluation, to assess tumor growth and
disease progression.
- We estimate that the accrual rate will be 3-10 patients per month; the total accrual
period for this study will be 10 months to 3 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01218555 -
Study of Everolimus (RAD001) in Combination With Lenalidomide
|
Phase 1 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Withdrawn |
NCT04614766 -
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Completed |
NCT02815969 -
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
|
||
Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02174549 -
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02134639 -
PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
|
N/A | |
Completed |
NCT02132468 -
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
|
Phase 2 | |
Recruiting |
NCT01201096 -
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
|
N/A | |
Terminated |
NCT01163526 -
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
|
N/A | |
Completed |
NCT01099228 -
Combination Targeted Radiotherapy in Neuroendocrine Tumors
|
N/A | |
Completed |
NCT00171873 -
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
|
Phase 3 | |
Active, not recruiting |
NCT05077384 -
Open-label Study of Surufatinib in Japanese Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04544098 -
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
|
Early Phase 1 | |
Active, not recruiting |
NCT02736500 -
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 |